NCT01968161

Investigator Initiated Study - Asenapine Early Psychosis

An Open-label Switch Study to Asenapine in the Early Stage of Psychosis

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

We propose a use of a unique facility, the databank at the CNDV, to examine the impact of switching subjects to asenapine in an open-label naturalistic setting. This offers the following advantages: i) providing data on a particularly important population, i.e., subjects who are at the inception of treatment for a psychotic disorder and who are likely to remain on a given drug on a long-term basis; ii) its inclusion in a rich clinical setting, with a clinical team dedicated to provide innovative interventions; iii) its naturalistic design, that will allow to obtain data that will be applicable to "real-life" clinical settings; indeed, subjects who will be switched to asenapine within the current project are those we would switch to this drug in our daily practice.

Conditions

• Schizophrenia and Disorders With Psychotic Features
• Disorders

Interventions

Type	Name	Description
DRUG	Asenapine

Timeline

• Start date: 2013-10-01
• Primary completion: 2014-02-01
• Completion: 2014-03-01
• First posted: 2013-10-23
• Last updated: 2014-01-09

Locations

1 site across 1 country: Canada